AIM ImmunoTech to Participate in the Virtual Investor Pitch Conference
AIM ImmunoTech will participate in the Virtual Investor Pitch Conference on June 17, 2024, at 1:00 PM ET. CEO Thomas K. Equels will deliver an elevator pitch outlining the company's upcoming milestones. Investors can submit questions live during the event, with responses provided within the time constraints. The live video webcast will be available on AIM ImmunoTech's website, with a replay accessible for 90 days.
- Participation in a high-visibility event like the Virtual Investor Pitch Conference can enhance AIM ImmunoTech's exposure to potential investors.
- CEO Thomas K. Equels will outline upcoming milestones, which may generate investor interest and support.
- The event allows direct engagement with investors, fostering transparency and trust.
- The webcast replay available for 90 days provides extended access, potentially reaching a wider audience.
- The press release lacks specific details about the upcoming milestones, which might leave investors wanting more substantial information.
- The event's impact on stock performance is uncertain and dependent on the content of the CEO's presentation and investor reactions.
Live video webcast on Monday, June 17th at 1:00 PM ET
OCALA, Fla., June 10, 2024 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”), today announced that Thomas K. Equels, MS JD, Chief Executive Officer of AIM will participate in the Virtual Investor Pitch Conference on Monday, June 17, 2024 at 1:00 PM ET.
As part of the event, Mr. Equels will provide an “elevator pitch” and outline the Company’s upcoming milestones. Additionally, investors and interested parties will have the opportunity to submit questions live during the event. Participating companies will answer as many questions as possible in the time allowed.
A live video webcast of the presentation will be available on the Events page of the Company’s website (aimimmuno.com). A webcast replay will be available two hours following the live presentation and will be accessible for 90 days.
About AIM ImmunoTech Inc.
AIM ImmunoTech Inc. is an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders and viral diseases, including COVID-19. The Company’s lead product is a first-in-class investigational drug called Ampligen® (rintatolimod), a dsRNA and highly selective TLR3 agonist immuno-modulator with broad spectrum activity in clinical trials for globally important cancers, viral diseases and disorders of the immune system.
For more information, please visit aimimmuno.com and connect with the Company on X, LinkedIn, and Facebook.
FAQ
When is AIM ImmunoTech participating in the Virtual Investor Pitch Conference?
Who will represent AIM ImmunoTech at the Virtual Investor Pitch Conference?
Will there be a replay available for the AIM ImmunoTech webcast?
Where can I watch the AIM ImmunoTech live video webcast?
What will CEO Thomas K. Equels discuss at the Virtual Investor Pitch Conference?
